<DOC>
	<DOCNO>NCT01704859</DOCNO>
	<brief_summary>The VITamin D OmegA-3 TriaL ( VITAL ; NCT 01169259 ) randomize clinical trial 25,874 U.S. men woman investigate whether take daily dietary supplement vitamin D3 ( 2000 IU ) omega-3 fatty acid ( OmacorÂ® fish oil , 1 gram ) reduce risk develop cancer , heart disease , stroke people prior history illness . This ancillary study conduct among participant VITAL examine whether vitamin D fish oil ( 1 ) reduce incident total fracture ( 2 ) reduce incident hip non-vertebral fracture .</brief_summary>
	<brief_title>Vitamin D Omega-3 Fatty Acids ( VITAL Trial ) : Effects Fractures</brief_title>
	<detailed_description>The VITAL : Effects Fracture Study ancillary study parent VITAL trial ( VITamin D OmegA-3 TriaL ) . The study require adjudication self-reported incident fracture event among 25,874 men woman . Findings ancillary study inform clinical practice role ( ) vitamin D and/or omega-3 fatty acid supplement fracture prevention . Because high prevalence low vitamin D level fracture old adult , trial enable u prove disprove whether high-dose vitamin D and/or fish oil supplementation effective primary prevention age-related osteoporotic fracture U.S . These nutritional supplement may offer low-cost preventative intervention reduce burden osteoporotic fracture potential substantial individual public health benefit .</detailed_description>
	<mesh_term>Fractures , Bone</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>All participant VITAL ( NCT 01169259 ) eligible participate ancillary study .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>fracture</keyword>
</DOC>